Meyer Handelman Company’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$26.2M Sell
431,165
-4,716
-1% -$275K 0.81% 41
2025
Q4
$23.5M Sell
435,881
-39,637
-8% -$1.91M 0.74% 45
2025
Q3
$21.4M Sell
475,518
-52,438
-10% -$2.45M 0.68% 47
2025
Q2
$24.4M Sell
527,956
-17,307
-3% -$850K 0.81% 39
2025
Q1
$33.3M Sell
545,263
-7,905
-1% -$461K 1.16% 28
2024
Q4
$31.3M Sell
553,168
-10,723
-2% -$599K 1.08% 31
2024
Q3
$29.2M Sell
563,891
-11,138
-2% -$522K 0.99% 35
2024
Q2
$23.9M Sell
575,029
-11,605
-2% -$519K 0.84% 37
2024
Q1
$31.8M Sell
586,634
-25,069
-4% -$1.28M 1.12% 30
2023
Q4
$31.4M Sell
611,703
-41,160
-6% -$2.16M 1.22% 30
2023
Q3
$37.9M Buy
652,863
+34,000
+5% +$2.08M 1.53% 17
2023
Q2
$39.6M Buy
618,863
+21,510
+4% +$1.44M 1.6% 13
2023
Q1
$41.4M Sell
597,353
-24,700
-4% -$1.74M 1.73% 13
2022
Q4
$44.8M Sell
622,053
-33,775
-5% -$2.55M 1.87% 11
2022
Q3
$46.6M Sell
655,828
-11,100
-2% -$805K 2.15% 8
2022
Q2
$51.4M Sell
666,928
-18,880
-3% -$1.44M 2.2% 7
2022
Q1
$50.1M Buy
685,808
+5,080
+0.7% +$341K 1.92% 7
2021
Q4
$42.4M Buy
680,728
+14,890
+2% +$873K 1.58% 14
2021
Q3
$39.4M Sell
665,838
-2,400
-0.4% -$158K 1.62% 14
2021
Q2
$44.7M Sell
668,238
-10,900
-2% -$711K 1.76% 10
2021
Q1
$42.9M Buy
679,138
+18,700
+3% +$1.16M 1.78% 12
2020
Q4
$41M Buy
660,438
+11,000
+2% +$676K 1.85% 12
2020
Q3
$39.2M Sell
649,438
-5,900
-0.9% -$355K 1.99% 10
2020
Q2
$38.5M Sell
655,338
-300
-0% -$17.9K 2.05% 10
2020
Q1
$36.5M Sell
655,638
-300
-0% -$18.3K 2.24% 9
2019
Q4
$42.1M Buy
655,938
+2,800
+0.4% +$160K 2.02% 11
2019
Q3
$33.1M Buy
653,138
+3,600
+0.6% +$169K 1.68% 15
2019
Q2
$29.5M Buy
649,538
+7,800
+1% +$363K 1.51% 17
2019
Q1
$32.7M Buy
641,738
+2,900
+0.5% +$144K 1.7% 16
2018
Q4
$33.2M Sell
638,838
-13,890
-2% -$746K 1.88% 14
2018
Q3
$40.5M Sell
652,728
-8,400
-1% -$498K 1.98% 12
2018
Q2
$36.6M Buy
661,128
+800
+0.1% +$43.2K 1.88% 13
2018
Q1
$41.8M Sell
660,328
-3,180
-0.5% -$205K 2.13% 10
2017
Q4
$40.7M Sell
663,508
-6,145
-0.9% -$384K 1.95% 12
2017
Q3
$42.7M Sell
669,653
-135,070
-17% -$7.89M 1.95% 12
2017
Q2
$44.8M Sell
804,723
-4,100
-0.5% -$223K 1.89% 10
2017
Q1
$44M Buy
808,823
+3,000
+0.4% +$165K 1.87% 11
2016
Q4
$47.1M Buy
805,823
+1,690
+0.2% +$92.4K 2.09% 11
2016
Q3
$43.4M Sell
804,133
-6,200
-0.8% -$398K 1.95% 11
2016
Q2
$59.6M Sell
810,333
-13,000
-2% -$919K 2.67% 7
2016
Q1
$52.6M Sell
823,333
-2,400
-0.3% -$151K 2.43% 7
2015
Q4
$56.8M Sell
825,733
-4,800
-0.6% -$317K 2.69% 7
2015
Q3
$49.2M Sell
830,533
-9,800
-1% -$622K 2.49% 7
2015
Q2
$55.9M Sell
840,333
-3,900
-0.5% -$257K 2.56% 7
2015
Q1
$54.5M Sell
844,233
-5,530
-0.7% -$346K 2.46% 7
2014
Q4
$50.2M Sell
849,763
-3,090
-0.4% -$174K 2.25% 9
2014
Q3
$43.6M Sell
852,853
-5,960
-0.7% -$298K 2.03% 10
2014
Q2
$41.7M Sell
858,813
-3,300
-0.4% -$163K 1.93% 11
2014
Q1
$44.8M Sell
862,113
-4,600
-0.5% -$245K 2.15% 8
2013
Q4
$46.1M Sell
866,713
-7,556
-0.9% -$385K 2.23% 8
2013
Q3
$40.5M Sell
874,269
-2,700
-0.3% -$119K 2.15% 10
2013
Q2
$39.2M Buy
+876,969
New +$38.1M 2.15% 10

Other funds holding BMY

Meyer Handelman Company's BMY Position: Q1 2026 in Review

Meyer Handelman Company reduced its Bristol-Myers Squibb (BMY) stake by 1.1% in Q1 2026, selling an estimated $275K and leaving 431,165 shares worth $26.2M. The position accounts for 0.81% of the portfolio, ranked #41.

Meyer Handelman Company first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $59.6M in Q2 2016. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Meyer Handelman Company held 431,165 shares of Bristol-Myers Squibb worth $26.2M as of Q1 2026.
  • Meyer Handelman Company sold 4,716 Bristol-Myers Squibb shares in Q1 2026, an estimated $275K.
  • Bristol-Myers Squibb made up 0.81% of Meyer Handelman Company's portfolio in Q1 2026, its #41 holding.
  • Meyer Handelman Company first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Meyer Handelman Company's Bristol-Myers Squibb position peaked at $59.6M in Q2 2016.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Meyer Handelman Company's 13F filing for Q1 2026, filed 20 Apr 2026.